We Offer Telehealth Appointments LEARN MORE

LAVIV™ (azficel-T) Available Now

LAVIV™™ (azficel-T) now Available at Silverberg Surgical In Newport Beach

Newport Beach, CA, Jan. 2012 – Silverberg Surgical is now offering LAVIV™™ (azficel-T), the first and only personalized cell therapy approved by the FDA for aesthetic use to improve the look of smile line wrinkles in adults. LAVIV™ is only available in select cities through board-certified dermatologists and plastic surgeons, such as Dr. Nancy Silverberg who have completed the comprehensive training program required by Fibrocell Science, Inc., the product manufacturer.

First and Only FDA-Approved Wrinkle Treatment Made from Your Own Collagen-Producing Skin Cells

Fibroblasts are responsible for producing collagen, which helps give skin its tone, structure and overall quality. As people age, the number of fibroblasts in their skin decreases and collagen breaks down, resulting in wrinkles and lost skin tone. The patented technology behind LAVIV™ is an advanced process that extracts a person’s fibroblast cells from a small skin sample and multiplies them in the Fibrocell Science lab. LAVIV™ is the resulting formulation of a person’s own fibroblast cells, which is then injected into smile line wrinkles. “Being able to offer this breakthrough treatment to my patients is exciting because LAVIV™ is made just for them,” said Dr. Silverberg “LAVIV™ is truly unique because each patient is being injected with their own collagen-producing fibroblast cells.” The recommended course of LAVIV™ administration is a series of three treatments, typically three to six weeks apart. Each person’s formulation of LAVIV™ is unique because it is made from their own collagen-producing fibroblast cells.

About Nancy Lee Silverberg, MD

A Board certified in dermatology, Dr. Nancy Lee Silverberg earned her medical degree the St. Louis University School of Medicine and her undergraduate degree from Cornell University, both with honors. She completed her residency training in Internal Medicine at the University of Arizona, and in Dermatology at the University of California, Irvine. Dr. Silverberg currently serves as an Associate Professor of Dermatology at UCI, and on the medical staff at Hoag Hospital where she serves as chairwoman of Dermatology. She specializes in Mohs micrographic surgery for skin cancer, and is a fellow of the American Society for Mohs Surgery.

Important Safety Information

LAVIV™ is made especially for you from your own skin cells. Using someone else’s cells can cause a serious reaction. Prior to injection, confirm with your physician that your information on the LAVIV™ vial is correct. The most common side effects of LAVIV™ are at the injection-site, including redness, bruising, swelling, pain, bleeding, lumps, irritation, and itchiness. In clinical trials with LAVIV™, most injection-site adverse reactions resolved within one week and most required no treatment.Your health care provider will help you to decide whether you are a candidate for LAVIV™ and may help you avoid some of the adverse reactions from LAVIV™. Before getting LAVIV™, tell your healthcare provider if you have any medical problems including allergic reactions to any drugs or food, bleeding disorders or take blood-thinning medicines like aspirin, ibuprofen, or coumadin, keloids or excessive scarring, skin cancer or any malignancy, genetic disorders affecting your skin, immune problems or take medicines that affect your immune system, or any other illness or medical problem. The full Prescribing Information for LAVIV™ includes additional warnings about adverse reactions that occurred in less than 1% of patients following LAVIV™ treatment in clinical trials. Talk to your healthcare provider about these warnings.Please tell your healthcare provider if you are allergic to the antibiotics amphotericin or gentamicin, bovine materials (products made from cattle), or dimethyl sulfoxide (DMSO). Do not use LAVIV™ if you have a skin infection on your face because LAVIV™ treatment can make the infection worse.

Posted on January 27, 2012 in Latest News | by

« Previous

Next »